Press releases
- ChromaDex to Join Russell 2000® Index
- Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
- ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
- ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
- ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
- ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
- ChromaDex Corporation Reports First Quarter 2024 Financial Results
- ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
- ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
More ▼
Key statistics
As of last trade, Chromadex Corp (OCD1:FRA) traded at 2.36, 100.00% above the 52 week low of 1.18 set on Oct 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.36 |
---|---|
High | 2.36 |
Low | 2.36 |
Bid | 2.30 |
Offer | 2.44 |
Previous close | 2.46 |
Average volume | 227.56 |
---|---|
Shares outstanding | 75.54m |
Free float | 48.51m |
P/E (TTM) | -- |
Market cap | 194.89m USD |
EPS (TTM) | -0.047 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 07:47 BST.
More ▼